

Tests for treatable causes of small-fiber polyneuropathy

Patient name
Medical record number
Date of birth

Date: ____/____/____

BLOOD TESTS TO CONSIDER FOR ADULTS

ordered today	not yet tested	abnormal value	normal value	
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chemistries (if glucose is high test for DM; if renal is high consider Fabry, mercury toxicity)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Complete blood count (if low, consider B12 or copper deficiency, lead/arsenic toxicity)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	AST, ALT (liver function; if abnormal consider hepatitis or alcohol)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hemoglobin A1c (if high, consider 2 hour GTT)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	TSH thyroid screening
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Vitamin B12 levels (if 200-500pg/dl consider methylmalonic acid level)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ESR (sedimentation rate; if elevated, consider inflammatory/dysimmune conditions)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANA (antinuclear antibodies; higher titers suggest lupus or dysimmune conditions)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Anti-Ro (SS-A) and anti-La (SS-B) (if present, consider Sjögren's disease)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	CRP (C-reactive protein; if elevated, consider inflammatory/dysimmune conditions)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Complement component C3 (if low, consider dysimmune conditions including lupus)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Complement component C4 (dysimmunity; if low C3+C4, consider classic pathway)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hepatitis C serology (if abnormal consider testing for cryoglobulins)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Lyme antibodies by Western blot (for inhabitant or visitor to endemic area)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	SPEP/IFIX (immunofixation tests for lymphoproliferative disorders)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Free κ/λ light chains (tests for less common lymphoproliferative disorders)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	IgA anti-TTG (transglutaminase antibodies; if present consider celiac sprue)

SECONDARY TESTS TO CONSIDER IN SPECIFIC POPULATIONS

ordered today	not yet tested	abnormal value	normal value	
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	2 hour, 75 g fasting glucose-tolerance test (strongly consider for all at risk for DM)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	HIV (CDC recommends everyone ages 13-64 be tested \geq once, high-risk more often)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phenotype-guided single gene sequencing (e.g., HSAN, SCN9A, Fabry, TTR)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Whole exome or genome sequencing (consider in children, strong family history)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Cryoglobulins, cryofibrinogens, viscosity (consider for myeloma, hep C, RA, SLE)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Pyridoxine (if high, consider vitamin B6 neurotoxicity, if low, consider B6 deficiency)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Anti-ds DNA, anti-Smith (consider if ANA present)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Urine protein electrophoresis to identify Bence Jones paraproteins
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	24 hour urine for arsenic, lead, mercury, cadmium (for artists, welders, miners)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Abdominal fat-pad biopsy for amyloid
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	OTHER TEST PERFORMED _____

Check for toxins and medications; e.g., cancer chemotherapy or immune checkpoint inhibitors, HIV therapy, colchicine, isoniazid, dapsone, hydralazine, lithium, phenytoin, vitamin B6, disulfiram, amiodarone, procainamide, perhexiline, streptokinase, nitrous oxide, metronidazole, nitrofurantoin, gold, thalidomide, TNF-antagonists, antimicrobials (chloramphenicol, fluoroquinolones, metronidazole, nitrofurantoin), history of GI surgery, malabsorption, alcoholism, exposure to inorganic arsenic, thallium, mercury, industrial toxins, organophosphate insecticides.

Tests reported as futile for general population screening in idiopathic SFN include serum ACE, heavy metals (arsenic, lead, mercury, cadmium), folic acid and vitamin B12 levels. Statin use was found not associated with SFN (Warendorf J. et al, Neurology, 2019).

References

- Lang M, Treister R, Oaklander A L. Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy. *J Neurology* 2016;263:2515-2527.
- Farhad K, Traub R, Ruzhansky KM, Brannagan TH, 3rd. Causes of neuropathy in patients referred as "idiopathic neuropathy". *Muscle Nerve* 2016;53(6):856-61.
- Gallagher G, Rabquer A, Kerber K, Calabek B, Callaghan B. Value of thyroid and rheumatologic studies in the evaluation of peripheral neuropathy. *Neurology: Clinical Practice* 2013;3:90-8.
- Peters MJ, Bakkers M, Merckies IS, Hoelijmakers JG, van Raak EP, Faber CG. Incidence and prevalence of small-fiber neuropathy: A survey in the Netherlands. *Neurology* 2013;81:1356-60.
- Bednarik J, Vlckova-Moravcova E, Bursova S, Belobradkova J, Dusek L, Sommer C. Etiology of small-fiber neuropathy. *J Peripheral Nervous System* 2009;14:177-83.
- England JD, Gronseth GS, Franklin G et al. Practice Parameter: Evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing. *Neurology* 72:185-192, 2009.
- de Sousa EA, Hays AP, et al. Characteristics of patients with sensory neuropathy diagnosed with abnormal small nerve fibres on skin biopsy. *JNeurolNeurosurgPsychiatry* 2006;77:983-5.
- Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. *Archives Internal Medicine* 9:1021-1025, 2004.